

## TABLE OF CONTENTS

	page
ACKNOWLEDGMENT	iii
ABSTRACT	iv
LIST OF TABLES	xii
LIST OF FIGURES	xiiiv
LIST OF ABBREVIATIONS	xvi
CHAPTER	
<b>I GENERAL INTRODUCTION</b>	1
1. Cellular drug resistance	1
1.1 Reduction in activity of DNA topoisomerase	1
1.2 Down-regulation of apoptosis	2
1.3 Changes in pH distribution in the cell	2
1.4 Overexpression of transporter proteins	3
1.4.1 P-glycoprotein	4
1.4.2 Multidrug resistance associated protein (MRP1)	5
2. Cellular energetic state and multidrug resistance phenotype	7
3. ABC-transporters in parasites related to ABC transporters in human cancer	8
4. Strategies to overcome multidrug resistance	9
5. Artemisinin and its derivatives	10
OBJECTIVES	11
REFERENCES	13
<b>II RHODAMINE B AS A MITOCHONDRIAL PROBE         FOR MEASUREMENT AND MONITORING OF         MITOCHONDRIAL MEMBRANE POTENTIAL IN         DRUG-SENSITIVE AND -RESISTANT CELLS</b>	20

ABSTRACT	21
1. INTRODUCTION	22
2. MATERIALS AND METHODS	23
2.1 Cell culture	23
2.2 Drugs and chemicals	23
2.3 Flow cytometric assay	23
2.4 Spectrofluorometric assay	24
2.5 Measurement of ATP in cell extracts	24
2.6 Reduction of 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT)	24
3. RESULTS AND DISCUSSION	24
3.1 Intracellular accumulation of rhodamine B by flow cytometry:	24
3.2 Estimation of the mitochondrial membrane potential by spectrofluorometry	26
3.2.1 Drug-sensitive cells	27
3.2.2 Drug-resistant cells	30
3.3 Determination of cellular ATP contents	33
4. CONCLUSION	34
5. REFERENCES	35
<b>III ASSESSMENTS OF THE LIVING DRUG-SENSITIVE AND -</b>	<b>38</b>
<b>RESISTANT CELLS RESPONSE TO ARTEMISININ, ARTESUNATE AND DIHYDROARTEMISININ BY <sup>1</sup>H-NMR SPECTROSCOPY AND BIOCHEMICAL STUDIES</b>	
ABSTRACT	39
1. INTRODUCTION	40
2. MATERIALS AND METHODS	41
2.1 Drugs and chemicals	41
2.2 Cell lines, cell culture and cytotoxicity assay	41
2.3 Induction of apoptosis.	42
2.4 Cytofluorometric staining of the cells.	42

2.5 NMR analysis	42
2.6 Flow cytofluorometric determination of cellular acridine orange uptake	43
3. RESULTS	43
3.1 <sup>1</sup> H-NMR spectra	43
a) <sup>1</sup> H-NMR spectra of untreated cells	43
b) <sup>1</sup> H-NMR spectra of treated cells	46
3.2 Determination of apoptosis by using flow cytometer	47
3.3 Determination of intracellular pH and intraluminal of lysosomal pH	47
4. DISCUSSION	49
5. REFERENCES	51
<b>IV MODULATION OF MULTIDRUG RESISTANCE BY ARTEMISININ, ARTESUNATE AND DIHYDRO-ARTEMISININ IN K562/ADR AND GLC4/ADR RESISTANT CELL LINES</b>	54
ABSTRACT	55
1. INTRODUCTION	55
2. MATERIALS AND METHODS	56
2.1 Cell Culture and Cytotoxicity Assay	56
2.2 Drugs and chemicals	57
2.3 Cellular drug accumulation	57
2.4 Determination of mitochondrial membrane potential	58
2.5 Measurement of ATP in cell extracts	60
3. RESULTS AND DISCUSSION	60
3.1 Co-treatment using pirarubicin and qinghaosu or doxorubicin and qinghaosu	60
3.2 Influence of artemisinin, artesunate and dihydro-artemisinin on cellular drug accumulation	64
3.3 Effect of artemisinin, artesunate, and dihydroartemisinin on mitochondrial function	65

4. REFERENCES	67
V GERNERAL DISCUSSION AND CONCLUSION	70
<b>APPENDIX</b>	
<b>A PROTON NMR VISIBLE MOBILE LIPID SIGNALS IN SENSITIVE AND MULTIDRUG RESISTANT K562 CELLS ARE MODULATED BY RAFTS.</b>	74
ABSTRACT	75
1. INTRODUCTION	76
2. MATERIALS AND METHODS	77
2.1 Chemicals	77
2.2 Cell culture	77
2.3 Cholesterol quantification	77
2.4 Cholesterol extraction using methyl- $\beta$ -cyclodextrin	77
2.5 Proliferation	77
2.6 Caveolin-1 detection : western-blot	78
2.7 Triton treatment	78
2.8 Sphingomyelinase treatment	78
2.9 NMR analysis	78
3. RESULTS	79
3.1 Cholesterol quantification	79
3.2 Cell proliferation after incubation with methyl- $\beta$ -cyclodextrin	80
3.3 Caveolin-1 expression : Western-Blot	81
3.4 $^1\text{H}$ -NMR spectra	81
a) Incubation with methyl- $\beta$ -cyclodextrin	81
b) Triton X-100 and sphingomyelinase treatments	83
4. DISCUSSION	84
5. CONCLUSIONS	87
6. REFERENCES	87

<b>B DECREASE OF P-GLYCOPROTEIN ACTIVITY IN K562/ADR CELLS BY M<math>\beta</math>CD AND FILIPIN AND LACK OF EFFECT INDUCED BY CHOLESTEROL OXIDASE INDICATE THAT THIS TRANSPORTER IS NOT LOCATED IN RAFTS</b>	90
ABSTRACT	91
1. INTRODUCTION	92
2. MATERIALS AND METHODS	93
2.1 Cell lines and culture	93
2.2 Drugs and chemicals	93
2.3 Determination of the cholesterol content of K562 cells	93
2.4 Cellular anthracycline accumulation	94
2.5 Determination of the P-gp-mediated efflux of anthracyclines	95
2.6 Treatment of cells with M $\beta$ CD	97
2.7 Treatment of cells with filipin	97
2.8 Incorporation of cholesterol into cholesterol-depleted cells	97
2.9 Treatment of cells with cholesterol oxidase.	97
2.10 Isolation of “light” and “heavy” membrane fractions	97
2.11 Western blotting measurement of P-glycoprotein expression	98
2.12 Localization of ganglioside GM1.	99
3. RESULTS	99
3.1 Non-esterified membrane cholesterol in sensitive and resistant cell lines.	99
3.2 Effect of M $\beta$ CD treatment on P-gp-mediated anthracycline transport.	99
3.3 Effect of cholesterol oxidation on P-gp activity.	101
3.4 Effect of filipin on P-gp functionality.	102
3.5 Assignment of source of membrane fractions.	102

4. DISCUSSION	103
5. REFERENCES	107
<b>CURRICURUM VITAE</b>	112



ลิขสิทธิ์มหาวิทยาลัยเชียงใหม่  
Copyright© by Chiang Mai University  
All rights reserved

## LIST OF TABLES

	page
<b>CHAPTER II</b>	
<b>Table 1</b> The mean coefficient of kinetics of rhodamine B uptake ( $K^+_{\text{rhoB}}$ ), the mean coefficient of kinetics of MTT uptake ( $K^+_{\text{MTT}}$ ), the mean coefficient of MTT-reduction ( $k^+_{\text{MTT-reduction}}$ ) by cells, and the absolute mitochondrial membrane potential values determined by using rhodamine B as molecular probe.	29
<b>Table 2</b> Lipophilic cations used to estimate the mitochondrial membrane potential ( $\Delta \Psi_m$ ).	29
<b>CHAPTER III</b>	
<b>Table 1</b> NMR signals integration reported to creatine peak integration measured on K562, GLC4, K562/ <i>adr</i> and GLC4/ <i>adr</i> spectra.	44
<b>Table 2</b> NMR peak ratios measured on K562, GLC4, K562/ <i>adr</i> and GLC4/ <i>adr</i> spectra obtained from the series of experiments described in the table 1.	45
<b>CHAPTER IV</b>	
<b>Table 1</b> Pattern of Cytotoxicity of Artemisinin, Artesunate and Dihydroartemisinin.	61
<b>Table 2</b> MDR reversing pattern of Artemisinin, Artesunate and Dihydroartemisinin.	61
<b>APPENDIX A</b>	
<b>Table 1</b> Quantification of cholesterol in K562 cells.	79
<b>Table 2</b> NMR peak ratios measured in K562wt and K562 <i>adr</i> spectra.	82
<b>Table 3</b> NMR peak ratios measured in K562wt and K562 <i>adr</i> spectra.	82
<b>APPENDIX B</b>	
<b>Table 1</b> Percentage of cellular cholesterol content after treatment with different M $\beta$ CD concentrations for various times.	99

## LIST OF FIGURES

	page
<b>CHAPTER I</b>	
Figure 1. Topology of the human P-glycoprotein.	6
Figure 2. Model of Multidrug resistance associated protein (MRP1).	7
Figure 3. Chemical structure of qinghaosu and its derivatives.	10
<b>CHAPTER II</b>	
Figure 1. Typical histograms of cell-rhodamine B bound fluorescence:	25
Figure 2. Typical histograms of cell-rhodamine B bound fluorescence:	27
Figure 3. Typical kinetics of the uptake of rhodamine B by cells.	30
Figure 4. Typical kinetics of the uptake of rhodamine B by cells.	31
Figure 5. Typical histograms of cell-rhodamine B bound fluorescence	32
Figure 6. Intracellular ATP levels of drug-sensitive and MDR cells.	33
Figure 7. Comparative cytotoxicity of pirarubicin to drug-sensitive cells;	34
<b>CHAPTER III</b>	
Figure 1. $^1\text{H-NMR}$ spectra obtained from K562, GLC4, K562/ <i>adr</i> and GLC4/ <i>adr</i> cells.	46
Figure 2. Representative biparametric histogram of an Annexin V-FITC versus PI of GLC4/ <i>adr</i> cells:	48
Figure 3. Apoptosis-inducing activity of dihydroartemisinin against K562, GLC4, K562/ <i>adr</i> and GLC4/ <i>adr</i> cells. The total apoptosis presents as a function time and concentrations	49
Figure 4. Changes in ratios of red to green fluorescence after 24 h (▨), 48 h (▩) and 72 h (▣) treatment using indicated concentration of dihydroartemisinin in (a) K562 and (b) K562/ <i>adr</i> cells.	50



## CHAPTER IV

- Figure 1.** Chemical Structure of Qinghaosu 57
- Figure 2.** The efficacy ( $\delta$ ) of molecules to enhance the cytotoxicity of pirarubicin and doxorubicin for K562/*adr* and GLC4/*adr*. 62
- Figure 3.** Effect of qinghaosu on pirarubicin (THP) accumulation in K562/*adr* cells. 63
- Figure 4.** Efficacy of artemisinin ( $\square$ ), artesunate (o) and dihydroartemisinin ( $\Delta$ ) to inhibit the P-glycoprotein-mediated THP efflux. 64
- Figure 5.** (a) Typical kinetics of the uptake of rhodamine B by cells. 65
- Figure 6.** Variation of  $\Delta\Psi_m$  (% of control) as a function of artemisinin ( $\square$ ), artesunate (o) and dihydroartemisinin ( $\Delta$ ) concentration in (a) K562, (b) K562/*adr*, (c) GLC4 and (d) GLC4/*adr* cells. 66
- Figure 7.** Intracellular ATP levels and the effect of 5  $\mu$ M artemisinin, artesunate or dihydroartemisinin on intracellular ATP levels of K562/*adr* and GLC4/*adr* cells. 67

## APPENDIX A

- Figure 1.** K562wt cells and K562*adr* cells were incubated for 2 hours in medium alone. 80
- Figure 2.** K562*adr* resistance modulation after MCD treatment. 81
- Figure 3.** NMR proton spectra obtained at D3 on K562wt (left side) and K562*adr* (right side) on control cells (top spectra) or treated with 5 mM MCD during 2 hours (bottom spectra). 83
- Figure 4.** K562wt  $^1\text{H}$ -NMR spectra : effects of Triton X-100 and sphingomyelinase treatments. 84
- Figure 5.** K562*adr*  $^1\text{H}$ -NMR spectra: effects of Triton X-100 and sphingomyelinase treatments. 85

## APPENDIX B

- Figure 1.** Spectrofluorometric method for the quantification of the cellular non esterified cholesterol. 95
- Figure 2.** Time course of uptake of pirarubicin (PIRA) by K562 cells after incubation with M  $\beta$ CD. 96
- Figure 3.** Incorporation of pirarubicin in energy-depleted cells K562/ADR cells and determination of the active efflux rate ( $V_a$ ). 98
- Figure 4.** Rate of the P-gp-mediated efflux of pirarubicin plotted as a function of the intracellular free pirarubicin concentration. 101
- Figure 5.** Rate ( $V_a$ ) of the P-gp-mediated efflux of PIRA as a function of the percentage of cholesterol in the cells. 102
- Figure 6.** Effect of cholesterol oxidase on the rate of P-gp-mediated efflux of pirarubicin and on the cellular cholesterol content. 102
- Figure 7.** Effect of filipin on the rate of P-gp-mediated efflux of pirarubicin and on the membrane permeability to doxorubicin. 103
- Figure 8.** Detection of GM1 and P-gp in K562/ADR cell lysates. 104

## LIST OF ABBREVIATIONS

MDR	Multidrug Resistance
P-gp	P-glycoprotein
MRP1-Protein	Multidrug Resistance Associated protein
ABC	ATP-binding Cassette
FCS	Fetal Calf Serum
ART	Artemisinin
ARTS	Artesunate
DHA	Dihydroartemisinin
MTT	3-(4,5-Dimethyl-2-thiazolyl)-2,5- diphenyl-2H-tetrazolium bromide (MTT)
CsA	Cyclosporine A
THP	Pirarubicin
Dox	Doxorubicin
$\Delta\Psi_m$	Mitochondrial membrane Potential
K562	Erythromyelogenous leukemia
GLC4	Small lung carcinoma
SDHase	Succinate dehydrogenase
%IC	Percentage of cell growth inhibition
R.F.	Resistance Factor
NMRS	Nuclear Magnetic Resonance Spectroscopy
$\lambda$	Wavelength